Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg, 5/5 µg), Tiotropium (2.5 µg, 5 µg) and Olodaterol (5 µg) (Oral Inhalation, Delivered by the Respimat® Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD) [VIVACITOTM]
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 219
- 试验地点
- 29
- 主要终点
- Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment.
研究概览
简要总结
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
tiotropium+olodaterol FDC high dose
tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
干预措施: Respimat (Device)
tiotropium low dose
tiotropium low dose; 2 inhalations once daily (a.m. dosing)
干预措施: tiotropium (Drug)
tiotropium low dose
tiotropium low dose; 2 inhalations once daily (a.m. dosing)
干预措施: Respimat (Device)
tiotropium high dose
tiotropium high dose; 2 inhalations once daily (a.m. dosing)
干预措施: Respimat (Device)
olodaterol
one dose only; 2 inhalations once daily (a.m. dosing)
干预措施: olodaterol (Drug)
tiotropium+olodaterol FDC low dose
tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
干预措施: tiotropium + olodaterol (Drug)
tiotropium+olodaterol FDC low dose
tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
干预措施: Respimat (Device)
tiotropium+olodaterol FDC high dose
tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
干预措施: tiotropium + olodaterol (Drug)
tiotropium high dose
tiotropium high dose; 2 inhalations once daily (a.m. dosing)
干预措施: tiotropium (Drug)
olodaterol
one dose only; 2 inhalations once daily (a.m. dosing)
干预措施: Respimat (Device)
placebo
2 inhalations once daily (a.m. dosing)
干预措施: Placebo (Drug)
placebo
2 inhalations once daily (a.m. dosing)
干预措施: Respimat (Device)
结局指标
主要结局
Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment.
时间窗: day 1 and week 6
Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 0 to 24 h post-dose, using the trapezoidal rule, divided by the duration (24 h) to report in litres. Mean is actually the Adjusted mean. The adjusted mean and standard error (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within-patient variation and Kenward-Roger approximation of denominator degrees of freedom.
次要结局
- FEV1 AUC0-12h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
- FEV1 AUC12-24h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
- Peak(0-3h) FEV1 Response [L] After 6 Weeks Treatment.(day 1 and week 6)
- Trough FEV1 Response [L] After 6 Weeks Treatment.(day 1 and week 6)
- FVC AUC0-24h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
- FVC AUC0-12h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
- FVC AUC12-24h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
- Trough FVC Response [L] After 6 Weeks Treatment.(day1 and week 6)
- Peak (0-3h) FVC Response [L] After 6 Weeks Treatment.(day 1 and week 6)
